AlphAIAlphAI — Financial news for AI agents
investing.com$LIVN

LivaNova PLC earnings beat by $0.17, revenue topped estimates

LivaNova PLC (LIVN) reported Q3 EPS of $1.23, beating estimates by $0.17, with revenue of $393.1M, exceeding expectations. The company guided FY 2026 EPS to $4.40-$4.50, above the consensus of $4.36. LIVN's stock is up 4.83% over 3 months and 57.25% over 12 months, with a 'great performance' financial health score according to InvestingPro.

Original reporting
investing.com
Published Nov 4, 2026, 11:13 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 11:22 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$LIVN
Bullish
high confidence
Mentioned
$LIVN
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$LIVNBullishHigh
01

Why it matters

Earnings beat and raised FY guidance could trigger short‑term buying interest.

02

Market read

The earnings surprise provides a fresh catalyst for LIVN and may influence peer valuations.

03

What to watch

Potential impact of upcoming regulatory reviews on product pipelines.

Relevance 8/10Novelty 8/10Timing: today

Background

LivaNova is a medical technology company listed on NASDAQ.

Company-level read

Ticker impact

$LIVNBullishHigh confidence
Context

LivaNova reported Q3 EPS of $1.23 beating estimates by $0.17 and revenue of $393.1M above consensus.

Expected impact

likely upward pressure as market prices in the earnings beat and raised FY guidance.

Evidence & confidence

The beat is a fresh primary disclosure with material numbers for a mid‑cap medical device company.

Market effects

Sector

May lift sentiment for the broader med‑tech sector.

Regional

U.S. investors may see modest buying in healthcare stocks.

Global

Limited to markets tracking U.S. listed med‑tech equities.

Counterpoint

What could challenge this read

Some investors may question sustainability of guidance if macro pressures rise.

Key entities

  • company
    LivaNova PLC

    Medical technology firm reporting Q3 results.

Read at source← All news

StoryLivaNova posts Q3 2026 earnings beat and lifts full‑year revenue and EPS guidance

Also covered by

6 outlets

Related articles

$LIVNMed

LivaNova PLC (LIVN) (Q3 2026) Earnings Call Highlights: Double-Digit Growth Fuels

LivaNova PLC (LIVN) reported Q3 2026 earnings with adjusted free cash flow declining to $56M from $62M YoY. SG&A expenses rose to $136M from $123M, and a $400M payment shifted to Q4, creating cash flow uncertainty. The company expects 1% FX tailwind but $5M tariff headwinds. Cardiopulmonary growth remains strong, with double-digit increases, and the next-gen oxygenator launch is on track for 2028.

finance.yahoo.com
$LIVNMed

LivaNova PLC Q3 2026 Earnings Call Summary

LivaNova PLC raised its full-year 2026 revenue guidance to 9-10% growth and adjusted EPS to $4.40-$4.50. Growth was driven by record Essence heart-lung machine placements, epilepsy volume growth, and reduced discounting. The company plans to enter the obstructive sleep apnea (OSA) market in 2027 and expects double-digit capacity expansion in 2027 due to new manufacturing lines. Management highlighted strong demand for oxygenators and strategic initiatives to support future growth.

finance.yahoo.com
$LIVNMed

Mizuho raises Livanova stock price target on Essenz placements

Mizuho raised its price target for Livanova (LIVN) to $115 from $95, citing strong U.S. Cardiopulmonary segment growth and Essenz placements. The stock has risen 48% in the past year, trading at $96.59. Livanova reported Q3 2026 earnings of $1.23 per share, beating estimates, and raised its full-year outlook. Jefferies also increased its price target to $120.

investing.com
$LIVNHighAI 8/10

Jefferies raises Livanova stock price target to $120 on guidance

Jefferies increased its price target for LivaNova (NASDAQ:LIVN) to $120 from $100, maintaining a Buy rating. The company reported Q3 sales of $393M, up 10%, and EPS of $1.23, up 20%, both beating estimates. LivaNova raised its full-year sales growth guidance to 9-10% and EPS guidance to $4.40-$4.50. The stock has a market cap of $5.33B and a PEG ratio of 0.12, according to InvestingPro.

investing.com